402 related articles for article (PubMed ID: 27976524)
1. Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies.
Wang LL; Burdick JA
Adv Healthc Mater; 2017 Jan; 6(1):. PubMed ID: 27976524
[TBL] [Abstract][Full Text] [Related]
2. The Delivery of RNA-Interference Therapies Based on Engineered Hydrogels for Bone Tissue Regeneration.
Yu T; Wang H; Zhang Y; Wang X; Han B
Front Bioeng Biotechnol; 2020; 8():445. PubMed ID: 32478058
[TBL] [Abstract][Full Text] [Related]
3. Local release of siRNA using polyplex-loaded thermosensitive hydrogels.
Fliervoet LAL; Zhang H; van Groesen E; Fortuin K; Duin NJCB; Remaut K; Schiffelers RM; Hennink WE; Vermonden T
Nanoscale; 2020 May; 12(18):10347-10360. PubMed ID: 32369076
[TBL] [Abstract][Full Text] [Related]
4. Controlled Release of RNAi Molecules by Tunable Supramolecular Hydrogel Carriers.
Bakker MH; van Rooij E; Dankers PYW
Chem Asian J; 2018 Nov; 13(22):3501-3508. PubMed ID: 29858562
[TBL] [Abstract][Full Text] [Related]
5. Sustained delivery of siRNA poly- and lipopolyplexes from porous macromer-crosslinked gelatin gels.
Schwabe K; Ewe A; Kohn C; Loth T; Aigner A; Hacker MC; Schulz-Siegmund M
Int J Pharm; 2017 Jun; 526(1-2):178-187. PubMed ID: 28456652
[TBL] [Abstract][Full Text] [Related]
6. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels.
Krebs MD; Jeon O; Alsberg E
J Am Chem Soc; 2009 Jul; 131(26):9204-6. PubMed ID: 19530653
[TBL] [Abstract][Full Text] [Related]
7. Development of new RNAi therapeutics.
Liu G; Wong-Staal F; Li QX
Histol Histopathol; 2007 Feb; 22(2):211-7. PubMed ID: 17149694
[TBL] [Abstract][Full Text] [Related]
8. Hydrogel microspheres for spatiotemporally controlled delivery of RNA and silencing gene expression within scaffold-free tissue engineered constructs.
McMillan A; Nguyen MK; Huynh CT; Sarett SM; Ge P; Chetverikova M; Nguyen K; Grosh D; Duvall CL; Alsberg E
Acta Biomater; 2021 Apr; 124():315-326. PubMed ID: 33465507
[TBL] [Abstract][Full Text] [Related]
9. Delivery of RNA interference.
Li CX; Parker A; Menocal E; Xiang S; Borodyansky L; Fruehauf JH
Cell Cycle; 2006 Sep; 5(18):2103-9. PubMed ID: 16940756
[TBL] [Abstract][Full Text] [Related]
10. Critical issues in delivery of RNAi therapeutics in vivo.
Rivera S; Yuan F
Curr Pharm Biotechnol; 2012 Jun; 13(7):1279-91. PubMed ID: 22201583
[TBL] [Abstract][Full Text] [Related]
11. Degradable poly(ethylene glycol) (PEG)-based hydrogels for spatiotemporal control of siRNA/nanoparticle delivery.
Wang Y; Zhang S; Benoit DSW
J Control Release; 2018 Oct; 287():58-66. PubMed ID: 30077736
[TBL] [Abstract][Full Text] [Related]
12. Mammalian RNAi: a practical guide.
Sandy P; Ventura A; Jacks T
Biotechniques; 2005 Aug; 39(2):215-24. PubMed ID: 16116795
[TBL] [Abstract][Full Text] [Related]
13. Sustained delivery of siRNA/PEI complex from in situ forming hydrogels potently inhibits the proliferation of gastric cancer.
Peng H; Yang H; Song L; Zhou Z; Sun J; Du Y; Lu K; Li T; Yin A; Xu J; Wei S
J Exp Clin Cancer Res; 2016 Mar; 35():57. PubMed ID: 27029190
[TBL] [Abstract][Full Text] [Related]
14. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
15. Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing.
Wang Y; Malcolm DW; Benoit DSW
Biomaterials; 2017 Sep; 139():127-138. PubMed ID: 28601703
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
[TBL] [Abstract][Full Text] [Related]
17. Injectable and protease-degradable hydrogel for siRNA sequestration and triggered delivery to the heart.
Wang LL; Chung JJ; Li EC; Uman S; Atluri P; Burdick JA
J Control Release; 2018 Sep; 285():152-161. PubMed ID: 29981357
[TBL] [Abstract][Full Text] [Related]
18. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
19. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
[TBL] [Abstract][Full Text] [Related]
20. Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference.
Li J; Wu C; Wang W; He Y; Elkayam E; Joshua-Tor L; Hammond PT
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2696-E2705. PubMed ID: 29432194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
